- Conditions
- Ureter Injury
- Interventions
- Indigotindisulfonate sodium 0.8%, Saline injection 0.9%
- Drug · Other
- Lead sponsor
- Prove pharm
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Albany, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 496
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cutaneous T-cell Lymphoma
- Interventions
- Vitamin B12, Folic Acid, Pralatrexate
- Dietary Supplement · Drug
- Lead sponsor
- Acrotech Biopharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 10
- States / cities
- Duarte, California • Redwood City, California • New Haven, Connecticut + 6 more
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- 0.9% Sodium Chloride, Furosemide 40 mg
- Drug
- Lead sponsor
- Adhish Agarwal
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Gender Dysphoria, Opioid Use, Pain, Postoperative
- Interventions
- Ropivacaine 0.2% Injectable Solution, Saline (0.9%)
- Drug · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Critical Illness, Enteral Nutrition, Enteral Feeding Intolerance
- Interventions
- TAK-954, Metoclopramide, Normal Saline
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 14
- States / cities
- Augusta, Georgia • Idaho Falls, Idaho • Peoria, Illinois + 11 more
- Conditions
- Peripheral Neuropathy Due to Chemotherapy
- Interventions
- IncobotulinumtoxinA (Xeomin®, Merz) (INA), Normal saline
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Interventions
- Peripheral blood draw, Bone marrow aspirate, Buccal swab
- Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Tennis Elbow
- Interventions
- TenoMiR, 0.9% Sodium Chloride Injection
- Drug
- Lead sponsor
- Causeway Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Redwood City, California • New York, New York
- Conditions
- PRP, Sexual Function Disturbances, Genitourinary Syndrome of Menopause, Postmenopausal Symptoms, Vaginal Atrophy
- Interventions
- Injection of platelet-rich plasma, Injection of saline
- Procedure
- Lead sponsor
- Medstar Health Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Knee Osteoarthritis
- Interventions
- PTP-01, Placebo control / saline vehicle
- Biological · Other
- Lead sponsor
- Doron Therapeutics Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • La Mesa, California • West Hills, California + 5 more
- Conditions
- Solid Tumor Refractory to Standard Therapy
- Interventions
- SQ001 125mL/day, SQ001 250mL/day, SQ001 500mL/day, SQ001 625mL/day, Saline 0.9%
- Drug
- Lead sponsor
- Livzon Pharmaceutical Group Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Cytomegalovirus Infection
- Interventions
- mRNA-1647, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • St Louis, Missouri • Seattle, Washington
- Conditions
- Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC), Colorectal Carcinoma (CRC)
- Interventions
- AZD4635, Durvalumab, Abiraterone Acetate, Enzalutamide, Oleclumab, Docetaxel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 17
- States / cities
- Fayetteville, Arkansas • Fresno, California • Denver, Colorado + 14 more
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- Plozasiran Injection, Placebo
- Drug
- Lead sponsor
- Arrowhead Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 446 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 52
- States / cities
- Garden Grove, California • Lake Forest, California • Montclair, California + 42 more
- Conditions
- Equinus Contracture
- Interventions
- Botulinum toxin type A, sodium chloride
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Pain, Head, Pain Syndrome, Temporomandibular Disorder, Myofascial Pain Syndrome, Myofascial Pain
- Interventions
- Botulinum toxin type A, 0.9% Sodium Chloride Injection
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • New York, New York
- Conditions
- Osteoporosis
- Interventions
- Zoledronic acid, Placebo, Teriparatide
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 45 Years to 89 Years · Female only
- Enrollment
- 412 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Beverly Hills, California • La Mesa, California + 15 more
- Conditions
- Hypertension, Resistant to Conventional Therapy
- Interventions
- Placebo - 1st Cycle, MANP - 1st Cycle, MANP - 2nd Cycle
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 20 Years to 70 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Biliary Tract Cancer
- Interventions
- NUC-1031, Gemcitabine, Cisplatin
- Drug
- Lead sponsor
- NuCana plc
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 773 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 29
- States / cities
- Tucson, Arizona • Whittier, California • Aurora, Colorado + 23 more
- Conditions
- Neuropathic Pain
- Interventions
- onabotulinum toxin A
- Drug
- Lead sponsor
- Isabel Moreno Hay
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Heterozygous Familial Hypercholesterolemia, Elevated Cholesterol
- Interventions
- Inclisiran, Placebo
- Drug
- Lead sponsor
- The Medicines Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 482 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 10
- States / cities
- Mission Viejo, California • Newport Beach, California • Stanford, California + 7 more
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- 744 Tablet, 744 LA Injection, Placebo Tablet, Placebo Injection
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 127 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 10
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more
- Conditions
- Healthy
- Interventions
- Ad26.ZEBOV 5*10^10 viral particles (vp), Ad26.ZEBOV 2*10^10 (vp), Ad26.ZEBOV 0.8*10^10 (vp), MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.], MVA-BN-Filo 5*10^7 Inf. U., Placebo
- Biological
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 525 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 6
- States / cities
- Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
- Conditions
- Trigger Finger Disorder
- Interventions
- Dexamethasone Sodium Phosphate, Xylocaine, Sodium Chloride
- Drug
- Lead sponsor
- Kenneth Taylor, M.D.
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania